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Abstract
Lesch-Nyhan disease is the most severe or complete phenotype of defi-
ciency in hypoxanthine-guanine phosphoribosyl transferase (HPRT). Other 
variant enzymes are found in patients without abnormality in behavior 
or mental development; and there are intermediate phenotypes in which 
enzyme activity is intermediate. A considerable number and variety of 
mutations in the HPRT gene have been discovered. [Tzu Chi Med J 2007;
19(3):105–108]
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1. Introduction
The most common of the diseases of purine metabolism 
and of the hyperuricemias of childhood is deficiency 
of hypoxanthine-guanine phosphoribosyltransferase 
(HPRT), and among patients with HPRT deficiency, the 
majority have the classic Lesch-Nyhan disease [1,2]. 
This X-linked recessive disorder of purine metabo-
lism results from deficiency of the activity of the 
enzyme HPRT (Fig. 1) [3]. HPRT deficiency leads to a 
variety of clinical phenotypes ranging in severity from 
the classic Lesch-Nyhan disease in which neurologic 
and behavioral features are seen, along with clinical 
manifestations of hyperuricemia that are shared with 
patients with gout to patients with normal neurology 
and behavior who have only manifestations directly 
attributable to uric acid, whom we have referred to 
as variants or partial variants. An intermediate group 
we have termed neurologic variants have a variety of 
Fig. 1 — Reactions catalyzed by hypoxanthine-guanine 
phosphoribosyltransferase.
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neurologic manifestations without the characteristic 
self-injurious behavior of the Lesch-Nyhan variant.
2. Clinical presentation
In the classic Lesch-Nyhan phenotype, affected infants 
develop normally for the first 4–6 months. The first 
sign of the disease is usually the appearance of what 
looks like orange sand in the diapers. Delayed neuro-
logic development becomes apparent within the first 
year; the child does not sit alone or loses this abil-
ity. Patients with this phenotype never learn to stand 
unassisted or to walk. Ultimately, if securely fastened 
around the chest or waist, the child can sit in a chair 
or wheelchair. During the first year, extrapyramidal 
signs develop. Involuntary movements may be choreic 
or athetoid as well as dystonic. Severe action dysto-
nia is the major motor feature.
Episodic opisthotonus or opisthotonic spasm regu-
larly present in our experience, reported in 25% [4], 
may lead to cervical spinal cord injury.
Signs of pyramidal tract involvement develop dur-
ing the first years of life, and the accompanying spas-
ticity is severe, often leading to dislocation of the hips. 
Patients have hyperreflexia and ankle clonus; a posi-
tive Babinski’s response is present in most. Scissoring 
the legs is common. Dysarthria and dysphagia are 
other features of the disease, and the dysarthria can 
combine with the motor defect and behavior to make 
proper assessment of mental capabilities difficult. Most 
patients eat poorly, and most of them vomit. Mental 
development may be retarded; the IQ, as measured, is 
usually in the range of 40–70. However, the behavior 
and motor defect make testing difficult. Some patients 
have had normal cognitive function, and a few have 
been successful mainstream students.
Aggressive, self-mutilative behavior is the single 
most distinctive feature of Lesch-Nyhan disease and 
in our experience has always been present in patients 
with the fully developed syndrome. Patients bite their 
lips, tongue and fingers, leading to loss of tissue and 
partial amputations. Patients are not insensitive to pain, 
and they scream in pain when they bite and are usually 
relieved when restrained to prevent self-injury. Physical 
restraints and extraction of teeth are the only effec-
tive methods of preventing the behavior. Aggressive 
behavior is also directed to others; patients bite, hit 
and kick. Detailed behavioral analysis of 22 patients 
revealed characteristic behavior/profiles of aggression, 
distractibility, anxiety and social problems [5].
Patients with HPRT deficiency are all hyperuricemic, 
and uric acid levels are between 5 and 10 mg/dL, while 
3–4 mg of uric acid per mg creatinine (1.9 ± 0.9 mmol/
mol creatinine) are found in the urine. Normal chil-
dren excrete less than 1 mg of uric acid/mg creati-
nine (0.2 mmol/mol creatinine). Patients may have 
normal serum levels if they are efficient excretors 
and may appear normal if adult male standards are 
used. Urinary data for uric acid can be spuriously low 
as a result of bacterial contamination. Accordingly, 
spot samples promptly frozen are better than 24-hour 
collections.
As a result of the accumulation of uric acid, patients 
manifest gout, arthritis, tophi, painful crystalluria, 
hematuria, nephrolithiasis, urinary tract infection and, 
in untreated patients, end-stage urate nephropathy.
Patients have also had megaloblastic anemia, severe 
enough in some to require blood transfusions. 
Macrocytosis or megaloblastic changes in the mar-
row have also been found in the absence of clinical 
anemia.
A preliminary diagnosis of classic Lesch-Nyhan syn-
drome can be made based on the phenotype. A serum 
concentration in a child of more than 4–5 mg uric 
acid/dL and a urine uric acid to creatinine ratio of 3–4 
are supportive. Definitive diagnosis requires analy-
sis of the HPRT activity of the HPRT enzyme. This is 
most conveniently assayed in erythrocytes. Dried 
blood spots on filter paper, as in newborn screening 
programs, provide for a stable source of enzyme for 
analysis of samples sent from distances.
3. The HPRT enzyme
HPRT (EC 2.4.2.8) catalyzes the reaction of 
hypoxanthine and guanine with 5-phosphoribosyl-1-
pyrophosphate (PRPP) to form the nucleotides inos-
inic acid (IMP) and guanylic acid (GMP) (Fig. 1). HPRT is 
actively expressed in the cytoplasm of every cell of the 
body; highest levels are found in the basal ganglia. In 
HPRT deficiency, the underutilization of hypoxanthine 
and guanine leads to increased excretion of the degra-
dation product uric acid, and the accompanying under-
utilization of PRPP gives rise to increased activity in the 
de novo pathway, increasing uric acid production.
In Lesch-Nyhan disease, the activity of HPRT in 
erythrocytes approximates zero [3,6]. Patients who do 
not have the full clinical phenotype of the classic Lesch-
Nyhan patient have activity that is low but not absent. 
Among the three groups, the classic Lesch-Nyhan dis-
ease, the neurologic variants, and those with hyper-
uricemia, no consistent correlation between enzyme 
activity as measured in the red cell lysate and clinical 
phenotype has emerged. However, when enzyme activ-
ity is measured in intact cultured fibroblasts, there is 
a rough inverse correlation between HPRT activity and 
the severity of clinical manifestations [6].
In partial variants with neurologic disease, hyper-
uricemia is present together with the typical extra-
pyramidal and pyramidal symptoms found in the 
classic Lesch-Nyhan patient. Intelligence is normal or 
near normal, and behavior may appear normal. The 
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neurologic examination of these patients is indistin-
guishable from that of the patient with classic Lesch-
Nyhan disease.
A distinct clinical phenotype with partial HPRT defi-
ciency (7.5% of normal enzyme activity) has been 
reported in a family with four affected members [7]. 
Each member displayed a phenotype of atypical neu-
rologic disease characterized by spasticity, increased 
deep tendon reflexes, and a positive Babinski’s 
response, but no dystonia or choreoathetosis; mental 
retardation was mild.
4. Molecular genetics
The gene for HPRT is coded on the X chromosome 
and mapped to the distal part of the long arm at 
position Xq2.6-Xq2.7. The disease is transmitted in 
an X-linked recessive fashion. It is almost exclusively 
a disease of the male, but seven affected females have 
been observed [8,9].
HPRT consist of 44 kb of DNA spread over 9 exons 
(Fig. 2). The gene is copied into the mRNA which 
is 1.6 kb in length but the actual reading frame, the 
piece that codes for the protein, is smaller. It contains 
217 amino acids in a subunit which then functions in 
a tetramer.
The 302 known mutations represent a wide vari-
ety. In general, each family has been found to have 
its own unique mutation in the HPRT gene [10,11]. 
Every possible type of mutation has been described 
within this gene: point mutations or single base sub-
stitutions leading to amino acid substitution; nonsense 
point mutations which lead to stop codons and trun-
cated proteins; point mutations at splice sites, nucle-
otide sequences that are designed to remove introns 
in the formation of mature mRNA, leading to a number 
of problems with the mRNA. For instance, one splice 
site mutation in a Lesch-Nyhan patient destroys the 
normal splicing site and reading goes from exon 1 
to exon 3, skipping exon 2. Another deletes exon 7. 
Splicing sites have consensus sequences that are 
conserved among the various splicing sites, and within 
the gene there are some sequences that are cryptic 
splicing sites which look like splicing sites. Some may 
be almost perfect sequences to lead to splicing site, 
but many do not function well. In some situations 
in the HPRT gene, the normal splice site is mutated 
and does not work, but a cryptic splice which is less 
functional nevertheless functions to some extent. 
In one instance, the cryptic splicing sites between 
exons 5 and 6 function so that exon sequences are 
not lost but a bit of the sequence of the intron is 
retained. Cryptic splicing within the exon also leads 
to removal of a piece of exon 9.
A number of deletions have been documented in 
the HPRT gene of Lesch-Nyhan patients. Deletions have 
been described for exon 4, exons 3, 6, and 7, while 
larger pieces of the gene have also been found, for 
instance deletion of exons 4 to 9 or even the whole 
gene. Genotype–phenotype correlations are emerg-
ing in this expanding database. In general, major dis-
ruptions such as deletions, large insertions, splice 
mutation, nonsense mutations or amino acid substi-
tutions that are not conservative are associated with 
the classical Lesch-Nyhan phenotype.
Among point mutations found in variants in whom 
there is some residual activity, there is often a con-
servative amino acid substitution. At any given posi-
tion in the gene, conservative change leads to variant, 
and a non-conservative change leads to the classical 
Lesch-Nyhan phenotype. For instance, in exon 2, there 
is normally a glycine at position 16. If it is changed to 
serine (a conservative change), the phenotype is variant. 
If it is changed to aspartic acid (a non-conservative 
change), the patient has the classic Lesch-Nyhan 
phenotype. In another example at position 194, when 
the acidic amino acid aspartic is changed to glutamic 
(a conservative transition), the phenotype is a variant, 
while a change to tyrosine or histidine (a very non-
conservative change) would lead to a Lesch-Nyhan 
phenotype. The nature of the mutation remains only 
a rough guide for predicting phenotype.
In general, phenotype correlates better with the 
amount of residual enzyme activity displayed in whole 
cell assays [6]. The classic Lesch-Nyhan disease is 
found when enzyme activity approximates zero, or 
close to it, and the partial phenotype occurs when 
an appreciable amount of enzyme activity can be 
demonstrated. A few exceptions have been reported 
in which classic phenotypes have accompanied rela-
tively sizable activities [12,13] or mild variant pheno-
type with no demonstrable enzyme activities [12–14]. 
Explanations for the exceptions include discrepancies 
between the activity of an aberrant enzyme structure 
Fig. 2 — Molecular biology of hypoxanthine-guanine phos-
phoribosyltransferase.
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when removed from its in vivo cellular environment, 
as has been demonstrated in difference between 
activity of an enzyme in lysates versus whole cell 
preparations. Also, mutations which change the kinet-
ics of an enzyme may be measured at very different 
concentrations, usually greater, than one finds in 
vivo. Some mutations are unstable; for instance, 
two duplications were reported to recombine, restor-
ing normal enzyme activity in some cells, creating a 
mosaic of normal and abnormal cells [12–14].
A considerable amount of information has been 
obtained from analysis of the nature of mutation. In 
a family in which the mutation is known, this is the 
method of choice for the detection of heterozygotes 
and for prenatal diagnosis. It can be of use in predict-
ing phenotype especially in a young presymptomatic 
infant born into a family with no precedent patients. 
Enzyme analysis via the intact well method remains 
the most reliable method for this purpose. As the 
issue of prognosis is so important, it is prudent in 
such an instance to utilize both methods.
References
 1. Lesch M, Nyhan WL. A familial disorder of uric acid metab-
olism and central nervous system function. Am J Med 
1964;36:561–70.
 2. Nyhan WL, Barshop BA, Ozand. Atlas of Metabolic Diseases, 
2nd edition. London: Hodder Arnold, 2005.
 3. Seegmiller JE, Rosenbloom FM, Kelley WN. Enzyme defect 
associated with a sex-linked human neurological dis-
order and excessive purine synthesis. Science 1967;155:
1682–4.
 4. Jinnah HA, Visser JE, Harris JC, et al. Delineation of the 
motor disorder of Lesch-Nyhan disease. Brain 2006;129:
1201–17.
 5. Schretlen DJ, Ward J, Meyer SM, et al. Behavioral aspects 
of Lesch-Nyhan disease and its variants. Dev Med Child 
Neurol 2005;47:673–7.
 6. Page T, Bakay B, Nissinen E, Nyhan WL. Hypoxanthine-
guanine phosphoribosyltransferase variants: correlation of 
clinical phenotype with enzyme activity. J Inherit Metab 
Dis 1981;4:203–6.
 7. Page T, Nyhan WL, Morena de Vega V. Syndrome of mild 
mental retardation, spastic gait, and skeletal malformations 
in a family with partial deficiency of hypoxanthine-guanine 
phosphoribosyltransferase. Pediatrics 1987;79:713–7.
 8. De Gregorio L, Jinnah HA, Harris JC, et al. Lesch-Nyhan 
disease in a female with a clinically normal monozygotic 
twin. Mol Genet Metab 2005;85:70–7.
 9. De Gregorio L, Nyhan WL, Serafin E, Chamoles NA. An 
unexpected affected female patient in a classical Lesch-
Nyhan family. Mol Genet Metab 2000;69:263–8.
10. Jinnah HA, De Gregorio L, Harris JC, Nyhan WL, O’Neill JP. 
The spectrum of inherited mutations causing HPRT defi-
ciency: 75 new cases and a review of 196 previously 
reported cases. Mutat Res 2000;463:309–26.
11. Nyhan WL. Inherited hyperuricemic disorders. Contrib 
Nephrol 2005;147:22–34.
12. Monnat RJ Jr, Chiaverotti TA, Hackmann AF, Maresh GA. 
Molecular structure and genetic stability of human hypox-
anthine phosphoribosyltransferase (HPRT) gene duplica-
tions. Genomics 1992;13:788–96.
13. Sege-Peterson K, Chambers J, Page T, Jones OW, Nyhan WL. 
Characterization of mutations in phenotypic variants of 
hypoxanthine phosphoribosyltransferase deficiency. Hum 
Mol Genet 1992;1:427–32.
14. Yang TP, Stout JT, Konecki DS, Patel PI, Alford RL, Caskey CT. 
Spontaneous reversion of novel Lesch-Nyhan mutation by 
HPRT gene rearrangement. Somat Cell Mol Genet 1988;14:
293–303.
